Big new round, big ambitions
Isomorphic Labs said on Tuesday it has raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz participating and Alphabet investing. The fresh capital is earmarked to design and develop new medicines using AI, and it follows a $2.1 billion Series B in May.
What the company is building
The roadmap is clear: scale foundational biology models, expand understanding of systemic disease, and push initial drug programs toward clinical trials. "When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said CEO Demis Hassabis. He added, "This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
Isomorphic says it is developing a proprietary drug design engine and an AI designed pipeline of therapeutic candidates to deliver a new generation of medicines.
New technologies reshape long term opportunities for investors who stay curious and adaptable. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
Leadership backdrop
Isomorphic spun out of DeepMind in 2021, and Hassabis has been CEO since the launch. He co-founded DeepMind before Google acquired it in 2014, and he stepped back as CEO of DeepMind three and a half months before this financing.
Why investors are leaning in
Funding for AI led drug discovery is setting records in 2026. Dealroom counts $23.2 billion raised by startups in the category this year. Big model players are circling too: Anthropic said in June it is launching an AI drug discovery program, and in April OpenAI partnered with Novo Nordisk. The bottom line: capital is concentrating around platforms that can translate molecular modeling into drug candidates faster, a theme to watch if your portfolio has exposure to biotech or AI infrastructure.
Learning how to use smarter tools can quietly improve investment decision making. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
